
10x Genomics, Inc. (NASDAQ: TXG) AI-Powered Stock Analysis
See how 10x Genomics, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
TXG●NASDAQ
HealthcareMedical - Healthcare Information Services
$46.27
$1.79(3.72%)
U.S. Market opens in 63h 26m
10x Genomics, Inc. (NASDAQ: TXG) AI-Powered Stock Analysis
See how 10x Genomics, Inc. scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer10x Genomics, Inc. (NASDAQ: TXG) Stock Overall Grade
10x Genomics, Inc.'s grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to 10x Genomics, Inc.'s overall NASDAQ stock rating.
Forecast
BScore
64/100Financial Growth
CScore
40/100Fundamental Growth
CScore
48/100Key Ratios
BScore
60/100Sector Comparison
AScore
80/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
58/10010x Genomics, Inc. (NASDAQ: TXG) AI-Powered Stock Analysis
On the NASDAQ, TXG demonstrates Good performance with an overall Forecast Score of 64/100 (B), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (48/100, C) highlight its stability, while Key Ratios (60/100, B) and Sector Comparison (80/100, A) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (58/100, C+) suggests High divergence in outlook.(NASDAQ: TXG) Component Analysis Explained
Understand the key factors behind each 10x Genomics, Inc. (NASDAQ: TXG) stock grade, including financials, comparisons, and forecasts.